Dr. Hadeel Salim Assad, MD

Dr. Assad practices at Karmanos Cancer Center in Detroit, Michigan, part of McLaren Health Care.

Dr. Assad's NPI, 1851684393, was assigned on May 17, 2011. Dr. Assad holds Michigan license 4301098397.

Dr. Assad's primary practice is Karmanos Cancer Center, at 4100 John R, Detroit, MI 48201 in Wayne County. The practice phone is (800) 576-6266.

Dr. Assad's primary practice is Karmanos Cancer Center in Detroit, Michigan, part of McLaren Health Care. Dr. Assad is also affiliated with DMC Harper University Hospital. The medical group on file is Wayne Health. Dmand AI also links Dr. Assad to 1 more medical group, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Assad practices, 2 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Assad's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Assad is licensed in Michigan.

CMS data shows 111 Medicare services from Dr. Assad across 3 procedure codes in 2024, for 77 Medicare patients. Medicare paid $7,385 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 77 Medicare patients who saw Dr. Assad in 2024. The largest group is 65 to 74, with 36 patients. 75% of them have cancer, and 75% have high blood pressure. 48% are also on Medicaid. Their average risk score is 2.32, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Assad's median patient age at 63, with 92% women.

In 2024, Dr. Assad wrote 425 Medicare Part D claims for 97 patients. 90% of them were for generic drugs. CMS names the drug for 283 of them, across 8 drugs with 11 or more claims each, at $221,740 in total drug cost. In 2023, CMS named 239 claims across 9 drugs.

Dr. Assad accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Assad as offering telehealth.

Dmand AI links 15 papers to Dr. Assad, published from 2014 to 2024. 2021 was the busiest year, with 3. The most frequent topics are Breast Neoplasms, Biomarkers, Tumor and BRCA1 Protein. Dr. Assad has published most often in Cancer Causes Control. Dr. Assad's most frequent co-authors are Nadine Abdallah, MD, Mandana Kamgar, MD and Asif Alavi, MD.

Dmand AI links Dr. Assad to 10 clinical trials, 4 of them phase 2 studies. 4 are still active or recruiting. Conditions studied include Breast Neoplasms, Breast Diseases and Triple Negative Breast Neoplasms. National Cancer Institute (NCI) sponsors the most, 3.

CMS Open Payments shows 127 general payments to Dr. Assad from 24 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 77% of the total. Gilead Sciences, Inc. paid the most, $55,071. It also lists 14 research payments totaling $34,225 in 2020.